MACC1 Antibody

What is MACC1 and why is it significant in cancer research?

MACC1 is a key driver of metastatic processes first identified in 2009, which initiates cellular proliferation, migration, invasion, and metastasis both in vitro and in vivo . Its significance lies in its established role as a strong prognostic biomarker across more than 20 different cancer entities . MACC1 functions as a transcriptional activator for MET and serves as a key regulator of HGF-MET signaling .

What are the primary applications of MACC1 antibodies in cancer research?

MACC1 antibodies are employed across multiple experimental platforms with varying methodological approaches:

For IHC applications, optimal antigen retrieval typically employs TE buffer at pH 9.0, with citrate buffer at pH 6.0 as an alternative . Research has demonstrated that properly optimized antibody dilutions are critical for specific detection while minimizing background signal.

How does MACC1 expression vary across different cancer types?

MACC1 expression patterns show distinct profiles across tumor types with significant clinical implications:

Interestingly, despite extensive research across numerous malignancies, there appears to be a significant research gap regarding MACC1 in prostate cancer, which warrants investigation given its prevalence as the second most common cancer in males .

Can MACC1 antibodies be used for liquid biopsies?

Yes, MACC1 antibodies have proven valuable in liquid biopsy applications, offering less invasive alternatives to tissue sampling. Multiple studies have successfully detected MACC1 transcripts in blood samples with significant clinical correlations :

In breast cancer, blood MACC1 level analysis achieved impressive diagnostic performance:

• Sensitivity: 96.7%

• Specificity: 92.5%

• Application: Differentiation between benign and malignant breast disease

For colorectal cancer screening:

• Sensitivity: 67%

• Specificity: 71%

• Application: Distinguishing colorectal adenoma patients from healthy controls

Recent research has also revealed that combining circulating cell-free ABCB1 transcripts (cfABCB1tx) with cell-free MACC1 transcripts (cfMACC1tx) provides enhanced prognostic stratification, with the cfABCB1tx-high/cfMACC1tx-high phenotype associated with worst prognosis in ovarian cancer patients .

What are the optimal protocols for using MACC1 antibodies in multiplex immunostaining?

Effective multiplex immunostaining with MACC1 antibodies requires careful methodological considerations:

Protocol Optimization:

• Antigen retrieval: TE buffer (pH 9.0) shows superior epitope retrieval compared to citrate buffer (pH 6.0)

• Blocking: 5-10% normal serum from the same species as secondary antibody

• Primary antibody: MACC1 antibody dilution must be empirically determined (recommended range: 1:20-1:200)

• Detection system: Polymer-based systems reduce cross-reactivity

For fluorescent multiplex applications:

• Select antibodies from different host species to avoid cross-reactivity

• Implement sequential staining if antibodies require different retrieval conditions

• Include appropriate controls:

  • Single-stained samples

  • Isotype controls

  • MACC1 knockdown/overexpression controls

When combining MACC1 with EMT markers (E-cadherin, N-cadherin, vimentin), sequential staining protocols have demonstrated superior results compared to simultaneous application . Signal amplification steps may be necessary when examining tissues with heterogeneous MACC1 expression levels.

How can researchers validate the specificity of MACC1 antibodies in their experimental systems?

Comprehensive validation requires multiple complementary approaches:

Genetic Manipulation Controls:

• MACC1 knockdown: Use lentivirus-mediated shRNA systems (e.g., H1299-pLKO-Teton-shMACC1)

• MACC1 overexpression: Employ inducible systems (e.g., A549-pTRE3G-Tet3G-MACC1)

• These manipulated systems provide crucial negative and positive controls for antibody specificity

Multi-technique Validation:

• Cross-validate findings across Western blot, IHC, and immunofluorescence

• Concordant results significantly increase confidence in antibody specificity

mRNA-Protein Correlation:

• Compare protein detection with RT-PCR or RNA-seq data for MACC1

• Strong correlation supports antibody specificity

Cross-reactivity Assessment:

• Test reactivity against known MACC1 homologs

• Evaluate species cross-reactivity (e.g., antibody 21970-1-AP shows reactivity with both human and mouse samples)

Western Blot Validation:

• Confirm band at expected molecular weight (canonical human MACC1: 852 amino acids, 96.6 kDa)

• Assess for non-specific bands

What mechanisms underlie MACC1-induced therapy resistance in cancer?

MACC1 mediates therapy resistance through multiple interconnected molecular mechanisms:

Chemoresistance Mechanisms:

• ABCB1 upregulation: MACC1 directly activates transcription of the multidrug resistance protein ABCB1, reducing intracellular accumulation of chemotherapeutic agents like doxorubicin

• Signaling pathway activation:

  • PI3K/AKT and ERK1/2 pathway activation contributes to cisplatin resistance in tongue squamous cell, ovarian, and lung cancers

  • Altered BCL2, BAD, and BAX expression levels affect apoptotic responses

• Metabolic reprogramming:

  • MACC1 induces the Warburg effect, promoting resistance to targeted therapies like trastuzumab in gastric cancer

  • lncRNA MACC1-AS1 regulates lipid oxidation and inhibits ferroptosis induced by chemotherapeutic drugs like gemcitabine

Radioresistance Mechanisms:

• MACC1 enhances DNA damage repair capabilities, allowing cancer cells to survive radiation-induced genotoxic stress

• The lncRNA FGD5-AS1/miR-497-5p/MACC1 axis has been implicated in radioresistance development in breast cancer

Immunotherapy Resistance:

• MACC1 regulates immune checkpoint molecules like PD-L1 on tumor cells, potentially affecting responses to checkpoint inhibitor therapies

• High MACC1 expression correlates with lower response rates to immune checkpoint inhibitors in colorectal adenocarcinoma

These findings have significant clinical implications, suggesting that MACC1-targeted therapies could potentially restore sensitivity to conventional treatments when used in combination approaches.

How does MACC1 contribute to cancer stem cell properties?

MACC1 plays a critical role in promoting cancer stemness through multiple mechanisms:

Expression in Stem Cell Populations:

• MACC1 shows significantly higher expression in ALDH+ cancer stem cell populations compared to ALDH- non-stem cells in lung cancer models

• Protein levels are upregulated in stemness-enriched 3D cultured spheroids compared to adherent monolayer cultures

Regulation of Stemness Markers:

• MACC1 upregulation promotes expression of key stemness transcription factors:

  • Sox2 and Nanog are significantly elevated in MACC1-high populations

  • The MACC1/Nanog/Oct4 axis has been identified as a key pathway in colorectal cancer progression

Dedifferentiation Process:

• MACC1 overexpression promotes the conversion of ALDH- non-stem cells into ALDH+ stem-like cells

• MACC1 knockdown suppresses the dedifferentiation process and reduces tumorigenic potential in vivo

Mechanistic Pathway:

• In certain contexts, MACC1 negatively regulates KLF4 expression through post-transcriptional mechanisms:

  • MACC1 silencing increases KLF4 gene stability, extending its half-life from 1.2h to 2.53h in H1299 cells

  • This regulation occurs without affecting KLF4 promoter activity

These findings have significant implications for targeting MACC1 to address therapy resistance and tumor recurrence mediated by cancer stem cell populations.

What methodologies exist for using MACC1 antibodies in therapeutic applications?

Several methodological approaches have been developed for MACC1-targeted therapies:

Chimeric Antibody Development:

• Chimeric antibodies like Chanti-MACC-1 have been engineered to specifically target MACC1

• These combine human constant regions with mouse variable regions to reduce immunogenicity while maintaining target specificity

Efficacy Testing Methodologies:

Clinical Potential:

• MACC1 antibody therapy has demonstrated significant efficacy in preclinical models:

  • Suppression of NSCLC cell proliferation, migration, and invasion

  • Tumor remission and extended survival in NSCLC-bearing mice

  • Blockade of the HGF/MET signaling pathway

Combination Strategies:

• Combining MACC1-targeted antibodies with conventional chemotherapy shows promise:

  • MACC1 inhibition can restore chemosensitivity by reducing ABCB1 expression

  • Statins have been shown to lower MACC1 levels and thereby ABCB1 as well, potentially enhancing treatment outcomes

How does MACC1 influence the tumor immune microenvironment?

MACC1 orchestrates complex changes in the tumor immune microenvironment through multiple mechanisms:

Immune Cell Infiltration and Polarization:

• MACC1 affects immune cell recruitment patterns:

  • In colon adenocarcinoma: Positive correlation with NK cells, neutrophils, and macrophages, but not with T cells, B cells, or dendritic cells

  • In breast cancer: Positive correlation with tumor-associated macrophages (TAMs), but negative correlation with NK cells and CD8+ cytotoxic T cells

Immunosuppressive Pathway Activation:

• HGF/c-MET pathway:

  • Alters cytokine profiles toward anti-inflammatory patterns (reduced IFN-γ, increased IL-4 and IL-10)

  • Promotes regulatory T cell (Treg) and M2 macrophage polarization

• Wnt/β-catenin signaling:

  • Reduces T cell recruitment into tumors

  • Affects chemokine secretion (CCL4, CCL5), reducing dendritic cell recruitment

  • Promotes WISP-1 secretion, enhancing TAM recruitment

• PI3K/Akt activation:

  • Shifts infiltration from cytotoxic T lymphocytes toward Tregs, M2 macrophages, and myeloid-derived suppressor cells (MDSCs)

  • Reduces pro-inflammatory cytokines IL-6 and TNF-α

Immune Checkpoint Regulation:

• MACC1 upregulation leads to increased PD-L1 expression in gastric cancer cells

• This creates an immune-protective effect for cancer cells in co-culture with peripheral blood mononuclear cells

• High MACC1 expression correlates with lower response rates to immune checkpoint inhibitors in colon adenocarcinoma

These findings suggest that MACC1-targeted therapies might enhance anti-tumor immunity by reversing immunosuppressive mechanisms, potentially increasing the efficacy of immune checkpoint inhibitors.

What are the common technical challenges when using MACC1 antibodies and how can they be addressed?

Researchers frequently encounter several technical challenges when working with MACC1 antibodies:

Subcellular Localization Variability:

• Challenge: MACC1 is present in both nuclear and cytoplasmic compartments , complicating consistent detection

• Solution: Optimize fixation and permeabilization protocols based on the compartment of interest:

  • For nuclear detection: More stringent permeabilization (0.5% Triton X-100)

  • For cytoplasmic detection: Milder permeabilization (0.1-0.2% Triton X-100)

Background Signal Issues:

• Challenge: Non-specific staining, particularly in IHC applications

• Solutions:

  • Extended blocking (1-2 hours) with 5-10% normal serum

  • Addition of 0.1-0.3% Tween-20 to wash buffers

  • Titration of antibody concentration (start with higher dilutions)

  • Use of polymer-based detection systems rather than avidin-biotin methods

Antibody Cross-Reactivity:

• Challenge: Potential cross-reactivity with related proteins

• Solutions:

  • Validate with genetic controls (MACC1 knockdown/overexpression)

  • Pre-adsorption with recombinant protein

  • Use antibodies targeting different epitopes to confirm findings

Variability Across Sample Types:

• Challenge: Different optimal conditions for cell lines versus tissue samples

• Solutions:

  • For tissues: Extended antigen retrieval (20-30 minutes)

  • For cell lines: Milder fixation (2-4% paraformaldehyde for 10-15 minutes)

  • Sample-specific titration of antibody concentrations

Western Blot Optimization:

• Challenge: Multiple bands or weak signal

• Solutions:

  • Reduced sample heating (70°C for 5 minutes instead of 95°C)

  • Addition of protease inhibitors during sample preparation

  • Use of PVDF membranes rather than nitrocellulose for better protein retention

  • Extended transfer times for high molecular weight detection

How should researchers interpret contradictory MACC1 expression data across different detection methods?

When faced with conflicting MACC1 expression data, researchers should employ a systematic analytical approach:

Common Contradictions and Resolution Strategies:

• Western Blot vs. IHC Discrepancies:

  • Possible causes: Tissue heterogeneity, epitope availability differences

  • Resolution: Microdissection of specific regions for Western blot analysis to match IHC regions of interest

  • Validation: Laser capture microdissection followed by qRT-PCR for mRNA confirmation

• mRNA vs. Protein Level Discrepancies:

  • Possible causes: Post-transcriptional regulation, protein stability differences

  • Resolution: Analyze MACC1 protein half-life and stability under experimental conditions

  • Validation: Pulse-chase experiments to assess protein turnover rates

• Antibody-Dependent Variations:

  • Possible causes: Different epitopes, clone specificities

  • Resolution: Use multiple antibodies targeting different MACC1 domains

  • Validation: Confirm with recombinant expression systems with epitope tags

• Cell Line vs. Patient Sample Differences:

  • Possible causes: Microenvironmental factors absent in cell culture

  • Resolution: Employ patient-derived xenografts or organoid models

  • Validation: Co-culture experiments to recreate tumor-stromal interactions

Methodological Framework for Resolution:

• Establish a hierarchy of evidence based on methodology robustness

• Implement orthogonal validation approaches (e.g., functional assays)

• Consider biological context (cancer type, stage, treatment history)

• Examine spatial and temporal factors (sampling time, tissue region)

• Evaluate technical variables (antibody lot, protocol differences)

When analyzing contradictory results in immune cell infiltration studies , researchers should consider single-cell analysis techniques to resolve apparent discrepancies between different cancer types.

What emerging technologies are enhancing MACC1 antibody applications in precision oncology?

Several cutting-edge technologies are revolutionizing MACC1 antibody applications:

Single-Cell Proteomics:

• Mass cytometry (CyTOF) with MACC1 antibodies enables simultaneous assessment of multiple parameters at single-cell resolution

• Applications: Identifies rare MACC1-expressing subpopulations within heterogeneous tumors

• Advantage: Correlates MACC1 expression with stem cell markers and immune phenotypes in the same cells

Spatially-Resolved Proteomics:

• Digital spatial profiling with MACC1 antibodies preserves tissue architecture context

• Applications: Maps MACC1 expression relative to immune cell infiltrates and stromal boundaries

• Relevance: Addresses findings regarding MACC1's influence on immune cell infiltration patterns

Liquid Biopsy Enhancements:

• Ultrasensitive detection methods for circulating MACC1 protein

• Applications: Real-time monitoring of treatment response and resistance development

• Clinical potential: Non-invasive companion diagnostics for MACC1-targeted therapies

Antibody Engineering Advancements:

• Bispecific antibodies targeting MACC1 and immune effector cells

• Applications: Combined targeting of MACC1+ cancer cells and immune activation

• Rationale: Addresses MACC1's role in immune evasion mechanisms

Nanobody Development:

• Smaller antibody fragments with enhanced tissue penetration

• Applications: Improved imaging and therapeutic delivery to MACC1-expressing tumors

• Advantage: Better access to nuclear MACC1 and densely packed tumor regions

These technologies are enhancing our understanding of MACC1 biology while simultaneously developing more effective diagnostic and therapeutic approaches.

What are the key knowledge gaps in MACC1 biology that antibody-based research could address?

Despite significant advances, several critical knowledge gaps remain in MACC1 biology:

Post-Translational Modifications:

• Current gap: Limited understanding of how PTMs regulate MACC1 function

• Research approach: Develop modification-specific antibodies (phospho-MACC1, etc.)

• Significance: May explain context-dependent MACC1 activities across cancer types

Isoform-Specific Functions:

• Current gap: Unknown functional differences between MACC1 splice variants

• Research approach: Isoform-specific antibodies for differential detection

• Significance: Could reveal tissue-specific functions and regulatory mechanisms

MACC1 in Prostate Cancer:

• Current gap: Notable absence of MACC1 studies in prostate malignancies despite being the second most common cancer in males

• Research approach: Comprehensive IHC profiling across prostate cancer stages

• Significance: Potential new biomarker for aggressive disease

Microenvironmental Regulation:

• Current gap: Limited understanding of how stromal factors influence MACC1 expression

• Research approach: Co-culture systems with antibody-based detection

• Significance: Could reveal mechanisms of context-dependent MACC1 activation

MACC1 in Therapy Resistance Evolution:

• Current gap: Dynamic changes in MACC1 during treatment resistance development

• Research approach: Sequential liquid biopsies with MACC1 detection

• Significance: Could identify early markers of resistance emergence

MACC1 in Non-Cancer Diseases:

• Current gap: Emerging associations with non-cancer conditions (Schwannoma, deafness, depression, pulmonary arterial hypertension)

• Research approach: Tissue-specific antibody profiling in affected tissues

• Significance: Could expand therapeutic applications beyond oncology

Addressing these knowledge gaps through antibody-based research would significantly advance our understanding of MACC1 biology and accelerate clinical applications.